Evidence map›Paper›PMID 17412710›Full record

ReviewSchizophrenia bulletin2007

Is COMT a susceptibility gene for schizophrenia?

Hywel J Williams, Michael J Owen, Michael C O'Donovan

Open access · bronzeAbstract readReview
In one paragraph

Review in Schizophrenia bulletin, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 175 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Copy Number Variations in Neuropsychiatric Disorders.International journal of molecular sciences · 2023
    Review
  8. Review
  9. Article
  10. The inconsistent mediating effect of catecholFrontiers in psychiatry · 2022
    Article
  11. Genetics of schizophrenia (Review).Experimental and therapeutic medicine · 2020
    Review
  12. An Investigation of theBalkan journal of medical genetics : BJMG · 2020
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Theranostic Biomarkers for Schizophrenia.International journal of molecular sciences · 2017
    Review
  18. Article
  19. Article
  20. Association study of single nucleotide polymorphism rs165599 ofMolecular biology research communications · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Hywel J WilliamsDepartment of Psychological Medicine, School of Medicine, Cardiff Uniiversity, Henry Wellcome Building, Health Park, Cardiff CF14 4XN, UK.
Michael J Owen
Michael C O'Donovan
Cardiff University · GB

Funding

Medical Research Council G9309834Medical Research Council G9810900Wellcome Trust
6 · The paper itself

Abstract

Catechol-O-methyl transferase (COMT) is a catabolic enzyme involved in the degradation of a number of bioactive molecules; of principal interest to psychiatry, these include dopamine. The enzyme is encoded by the COMT gene. COMT is located (along with 47 other genes) in a fragment of chromosome 22q11 which when deleted results in a complex syndrome, the psychiatric manifestations of which include schizophrenia and other psychoses. These 2 observations have placed COMT near the top of a rather long list of plausible candidate genes for schizophrenia. The ability to test the hypothesis that COMT might be a susceptibility gene for schizophrenia has been simplified in principle by the existence of a valine-to-methionine (Val/Met) polymorphism which results respectively in high and low activity forms of the enzyme. Given the unequivocal effect of this polymorphism on the function of COMT, and the evidence for a critical role for dopamine in the pathophysiology and treatment of psychosis, there are strong prior expectations that Val/Met influences susceptibility to schizophrenia as well as other psychiatric phenotypes. Indeed the Val/Met polymorphism has become the most widely studied polymorphism in psychiatry. In this review, we consider the evidence for and against the involvement of COMT in schizophrenia. The current data allow us to virtually exclude a simple relationship between schizophrenia and the Val/Met variant previously thought to dominate COMT function. However, recent data suggest a more complex pattern of genetic regulation of COMT function beyond that attributable to the Val/Met locus. Moreover, it is also clear that there is a complex nonlinear relationship between dopamine availability and brain function. These 2 factors, allied to phenotypic complexity within schizophrenia, make it difficult to draw strong conclusions regarding COMT in schizophrenia. Nevertheless, emerging research that takes greater account of all these levels of complexity is beginning to provide tantalizing, but far from definitive, support for the view that COMT influences susceptibility to at least some forms of psychosis.

Indexed as

AllelesCatechol O-MethyltransferaseChromosome DeletionChromosome MappingChromosomes, Human, Pair 22DopamineGenetic Predisposition to DiseaseHumansMethioninePolymorphism, GeneticPrefrontal CortexSchizophreniaValineCatechol O-MethyltransferaseDopamineMethionineValine

Identifiers

PMID17412710
PMCPMC2526139
OpenAlexW2136423020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.